Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3701-3710 Newer>

The Motley Fool May 9, 2007 Brian Lawler	Where Is Momenta's Momentum? Momenta awaits an FDA regulatory decision and announces quarterly financial results. Investors, take note.
The Motley Fool May 9, 2007 Brian Lawler	Diagnosing Dendreon Postmortem The FDA issues an approvable letter for Dendreon's top compound. Investors, take note.
The Motley Fool May 9, 2007 Tim Beyers	Who's Filing Now? Take a look at what lurks in late filings from Friday. Isis Pharmaceuticals responded to concerns regarding the independence of director Dr. Richard DiMarchi by ending a $12,000-a-year consulting contract it had with him.
The Motley Fool May 8, 2007 Brian Lawler	Neurocrine Is Waking Up After being put to sleep for much of 2006 following an unexpected FDA smackdown on its lead drug, indiplon, shares of the biopharma have boosted over 50% higher versus its lows last year.
The Motley Fool May 8, 2007 Brian Lawler	Unstoppable Celgene The biotech powerhouse continues its strong financial results as Revlimid sales grow.
The Motley Fool May 8, 2007 Ryan Fuhrmann	CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results.
Reason May 2007 Jacob Sullum	Exporting Drug Prices Pharmaceutical companies argue that the higher prices paid by Americans underwrite the research and development that makes new drugs possible, in effect subsidizing consumers in other countries. Reimportation could force our northern neighbors to share that burden.
The Motley Fool May 7, 2007 Mike Havrilla	Critical Therapeutics' Juncture With approval likely, the real challenge will be selling an asthma drug once it's on the market. While shares may get a brief bounce, this may not be a case of "if you approve it, they will prescribe."
The Motley Fool May 7, 2007 Mike Havrilla	Advanced Life Makes Progress After positive data in an anthrax study, Advanced Life Sciences' potential antibiotic cethromycin has been granted FDA Orphan Drug status for this indication. Investors, take note.
The Motley Fool May 7, 2007 Brian Orelli	Introgen's Still Standing -- for Now With a lack of products, the biotech's burn rate is a key factor for investors to figure out its chance of survival.
<Older 3701-3710 Newer> Return to current articles.